Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AbbVie
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
Gilead Sciences
University of Washington
Mayo Clinic
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
BeOne Medicines
BeOne Medicines
University of Ulm
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University of Ulm
Acerta Pharma BV
French Innovative Leukemia Organisation
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
City of Hope Medical Center
Fred Hutchinson Cancer Center
Janssen Pharmaceutical K.K.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Ulm